{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:25:08Z","timestamp":1777325108987,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtm.2024.101375","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:31:50Z","timestamp":1731443510000},"page":"101375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Jolanda M.P.","family":"Liefhebber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giso","family":"Brasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A.","family":"Spronck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roelof","family":"Ottenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieke","family":"Paerels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas K.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoleta","family":"Efthymiopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Lin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula S.","family":"Montenegro-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Poi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101375_bib1","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2024.101375_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-020-02034-2","article-title":"Evolving AAV-delivered therapeutics towards ultimate cures","volume":"99","author":"He","year":"2021","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.omtm.2024.101375_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2024.101375_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2024.101375_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and screening of patients with Fabry disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtm.2024.101375_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/biom12101460","article-title":"An overview of molecular mechanisms in Fabry disease","volume":"12","author":"Amodio","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtm.2024.101375_bib7","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.522","article-title":"Renal manifestations in Fabry disease and therapeutic options","author":"Torra","year":"2008","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.omtm.2024.101375_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2024.101375_bib9","doi-asserted-by":"crossref","first-page":"s10","DOI":"10.1590\/1806-9282.66.s1.10","article-title":"Fabry disease: genetics, pathology, and treatment","volume":"66","author":"Bernardes","year":"2020","journal-title":"Rev. Assoc. Med Bras (1992)"},{"key":"10.1016\/j.omtm.2024.101375_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101375_bib11","series-title":"Fabrazyme [package Insert]","year":"2023"},{"key":"10.1016\/j.omtm.2024.101375_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101375_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101375_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/jgm.1391","article-title":"Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice","volume":"11","author":"Ishiwata","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2024.101375_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/hum.2008.161","article-title":"Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer","volume":"20","author":"Cooper","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib18","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-\u03b1-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib19","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101375_bib20","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101375_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101375_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ymgme.2011.06.002","article-title":"Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates","volume":"104","author":"Bell","year":"2011","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101375_bib23","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5(ch) and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1089\/hum.2016.160","article-title":"Adeno-associated virus gene therapy for liver disease","volume":"27","author":"Kattenhorn","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib25","first-page":"53","article-title":"Prevalence and affinity\/avidity assessment of pre-existing NABs against AAV1, 2, 5\u00a0and 8 analyzed in the serum of 300 healthy donors","volume":"26","author":"Majowicz","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.omtm.2024.101375_bib26","first-page":"557","article-title":"Prevalence and affinity\/avidity assessment of pre-existing neutralizing antibodies (NABs) against adeno-associated virus (AAV) vector serotypes 2, 5 and 8 analyzed in the serum of 300 healthy donors","volume":"4","author":"Majowicz","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.omtm.2024.101375_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib29","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtm.2024.101375_bib30","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.omtm.2024.101375_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of \u03b1-galactosidase A","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib32","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.omtm.2024.101375_bib33","article-title":"Phase 1\/2 clinical trial evaluating 4D-310 in adults with Fabry disease cardiomyopathy: interim analysis of cardiac and safety outcomes in patients with 12-33\u00a0months of follow-up [oral presentation]","author":"Thomas","year":"2024","journal-title":"Annual WORLDSymposium"},{"key":"10.1016\/j.omtm.2024.101375_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3560","article-title":"Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in \u03b1-galactosidase A-deficient mice","volume":"25","author":"Hayashi","year":"2023","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2024.101375_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.10.016","article-title":"Systemic treatment of Fabry disease using a novel AAV9 vector expressing \u03b1-Galactosidase A","volume":"20","author":"Biferi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101375_bib36","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1089\/hum.2023.222","article-title":"Developing gene therapy for mitigating multisystemic pathology in Fabry disease: proof of concept in an aggravated mouse model","volume":"35","author":"Boukharov","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib37","article-title":"Development of a novel gene therapy for Fabry disease: engineered alpha-galactosidase A transgene for improved stability [poster]","author":"Willer","year":"2021","journal-title":"Annual WORLDSymposium"},{"key":"10.1016\/j.omtm.2024.101375_bib38","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1038\/s41598-023-31777-4","article-title":"Optimizing human \u03b1-galactosidase for treatment of Fabry disease","volume":"13","author":"Hallows","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101375_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101375_bib40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101375_bib41","article-title":"Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: results from the MARVEL-1 phase 1\/2 clinical trial [oral presentation]","author":"Hughes","year":"2022","journal-title":"Annual WORLDSymposium"},{"key":"10.1016\/j.omtm.2024.101375_bib42","article-title":"Isaralgagenecivaparvovec(ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing Phase 1\/2 study (STAAR) [oral presentation]","author":"Hopkin","year":"2024","journal-title":"Annual WORLDSymposium"},{"key":"10.1016\/j.omtm.2024.101375_bib43","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0537900100","article-title":"Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer","volume":"100","author":"Park","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101375_bib44","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","article-title":"Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer","volume":"99","author":"Takahashi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101375_bib45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fneur.2017.00335","article-title":"Changes in ionic conductance signature of nociceptive neurons underlying Fabry disease phenotype","volume":"8","author":"Namer","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtm.2024.101375_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916646379","article-title":"Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development","volume":"12","author":"\u00dc\u00e7eyler","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.omtm.2024.101375_bib47","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101375_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.omtm.2024.101375_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101375_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cca.2017.01.014","article-title":"Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS\/MS with identical (13)C-encoded internal standards","volume":"466","author":"Mirzaian","year":"2017","journal-title":"Clin. Chim. Acta"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:06:48Z","timestamp":1737666408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2329050124001918"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101375","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 uniQure Biopharma B.V. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101375"}}